MedTrace Logo

Aliya™ Pulsed Electric Fields (PEF) for Advanced Cancer

NCT05890872 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-08-20

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate safety of delivering Aliya PEF in patients with metastatic cancer within the lungs or stage IV non-small cell lung cancer (NSCLC) who are treatment-naïve and indicated for first-line standard of care (SOC) cancer therapy.

Conditions

  • Lung Neoplasm Malignant

Interventions

DEVICE

Aliya Pulsed Electric Fields (PEF)

Percutaneous or Endobronchial PEF

Sponsors & Collaborators

  • Galvanize Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • William Krimsky, MD · Chief Medical Officer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-06
Primary Completion
2025-08-13
Completion
2025-08-13
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05890872 on ClinicalTrials.gov